Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

What is the key outcomes analysis of the Global Dermatology Drugs Market? Players evolve: Pfizer, Amgen, Novartis, Bayer, Johnson & Johnson

share with twitter share with LinkedIn share with facebook
share via e-mail
08/09/2019 | 05:37am EDT

Dermatology Drugs Comprehensive Study by Type (Prescription-Based Drugs, Over-the-Counter Drugs), Application (Psoriasis, Skin Infections, Acne, Dermatitis, Other), Forms (Tablets, External Use, Injection) Players and Region - Global Market Outlook to 2024.

Dermatology drugs are used to treat numerous skin conditions, these drug are applied directly on the skin or can be taken through injection. They may deliver medicines to prevent or treat skin disorders or have inert creams and gels for routine skin care to maintain the skin, which may be liable to skin disorders.

A large number of drugs have been approved by the FDA and other regulatory bodies of different countries for some skin conditions and disorders. The dermatological indications such as pigmentation, acne, wrinkles, psoriasis and many other can be treated by the dermatology drugs.

This intelligence report provides a comprehensive analysis of the "Global Dermatology Drugs Market. This includes Investigation of past progress, ongoing market scenarios, and future prospects. Data True to market on the products, strategies and market share of leading companies of this particular market are mentioned. It's a 360-degree overview of the global market's competitive landscape. The report further predicts the size and valuation of the global market during the forecast period.Some of the key players profiled in the study are Bayer AG (Germany), Johnson & Johnson (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), GlaxoSmithKline plc (United Kingdom), AstraZeneca (United Kingdom), Galderma S.A (Switzerland), Amgen Inc. (United States), AbbVie Inc. (United States) and Merck KGaA. (Germany).

Free Sample Report + All Related Graphs & Charts @ : https://www.advancemarketanalytics.com/sample-report/108088-global-dermatology-drugs-market

Market Drivers

*Growing Demand for Topical Dermatological Drugs

Market Trend

*Rising Expenditure on Personal Care


*Strict Government Regulations


*Development of Innovative Products


*Side Effect Related to Dermatology Drugs

Each segment and sub-segment is analyzed in the research report. The competitive landscape of the market has been elaborated by studying a number of factors such as the best manufacturers, prices and revenues. Global Dermatology Drugs Market is accessible to readers in a logical, wise format. Driving and restraining factors are listed in this study report to help you understand the positive and negative aspects in front of your business.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market.

Furthermore, the years considered for the study are as follows:

Historical year - 2013-2017

Base year - 2018

Forecast period** - 2019 to 2025 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/108088-global-dermatology-drugs-market

Segmentation and Targeting:

The Study Explore the Product Types of Dermatology Drugs Market: Prescription-Based Drugs, Over-the-Counter Drugs

Key Applications/end-users of Global Dermatology Drugs Market: Psoriasis, Skin Infections, Acne, Dermatitis, Other

Forms: Tablets, External Use, Injection

Top Players in the Market are: Bayer AG (Germany), Johnson & Johnson (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), GlaxoSmithKline plc (United Kingdom), AstraZeneca (United Kingdom), Galderma S.A (Switzerland), Amgen Inc. (United States), AbbVie Inc. (United States) and Merck KGaA. (Germany)

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Objectives of the Study

*To Define, Describe, and Segment The Global Dermatology Drugs Market On The Basis Of Type, Function, Application, And Region.

*To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and industry-specific challenges)

*To estimate the size of the Global Dermatology Drugs Market in terms of value.

*To study the individual growth trends of the providers of Global Dermatology Drugs Market, their future expansions, and analyze their contributions to the market

*To strategically analyze micro-markets with respect to individual growth trends, future prospects, and contribution to the total market, covered by Global Dermatology Drugs Market and various regions.

*To track and analyze competitive developments such as joint ventures, mergers & acquisitions, and new product launches, in Global Dermatology Drugs Market.

*To strategically profile key market players and comprehensively analyze their market position and core competencies

Read Detailed Index of full Research Study at @ https://www.advancemarketanalytics.com/reports/108088-global-dermatology-drugs-market

Extracts from TOC

1 Study Coverage

Industry Definition


2 Executive Summary

Global Dermatology Drugs Market Size (2014-2025) by Revenue, Production*, Growth rate

Analysis of Competitive Landscape - Insights on Market Development Scenario

3 Market Size by Manufacturers [Market Share, Global Rank etc]

4 Global Dermatology Drugs Production, Consumption by Regions (2014-2025)

5 Market Size by Type

Global Dermatology Drugs Revenue by Type

Global Dermatology Drugs Volume by Type

Global Dermatology Drugs Price by Type

6 Market Size by Application (2014-2025)

Global Dermatology Drugs Breakdown Data by Revenue, Volume

7 Manufacturers Profiles

8 Value Chain and Sales Channels Analysis

Buy the Latest Detailed Report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=108088

Key questions answered

*Who are the Leading key players and what are their Key Business plans in the Global Dermatology Drugs market?

*What are the key concerns of the five forces analysis of the Global Dermatology Drugs market?

*What are different prospects and threats faced by the dealers in the Global Dermatology Drugs market?

*What are the strengths and weaknesses of the key vendors?

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Media Contact

Company Name: AMA Research & Media LLP

Contact Person: Craig Francis

Email: info@advancemarketanalytics.com

Phone: +1 (206) 317 1218

Address:Unit No. 429, Parsonage Road Edison, NJ New Jersey USA - 08837

City: New Jersey

State: New Jersey

Country: United States

Website: https://www.advancemarketanalytics.com

Source: www.abnewswire.com


(C) 2019 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN 0.66% 196.94 Delayed Quote.1.17%
BAYER AG 0.49% 67.23 Delayed Quote.10.47%
JOHNSON & JOHNSON 1.18% 131.65 Delayed Quote.0.82%
NOVARTIS 0.44% 86.26 Delayed Quote.16.11%
PFIZER 0.49% 36.69 Delayed Quote.-15.95%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
09/20BAYER : data at ESMO 2019 highlights innovation in cancer research
09/19Animal health sector aims to emulate Zoetis biotech leap
09/19Biotech is going to the dogs - and big profits await
09/17BAYER : Invests $20 Million in U.S.-Based Informed Data Systems
09/17BAYER : and Informed Data Systems Inc. to develop One Drop digital therapeutics ..
09/11BAYER : opens application window for Grants4Traits™ and Grants4Biologicals..
09/10BAYER : to reduce size of management board to five
09/10BAYER : to Reduce Size of Management Board
09/10BAYER : reduces size of Board of Management from seven to five members
09/10BAYER : launches latest fungicide innovation, iblon™ technology
More news
Financials (EUR)
Sales 2019 46 036 M
EBIT 2019 7 933 M
Net income 2019 3 131 M
Debt 2019 37 298 M
Yield 2019 4,24%
P/E ratio 2019 21,4x
P/E ratio 2020 13,8x
EV / Sales2019 2,17x
EV / Sales2020 2,05x
Capitalization 62 695 M
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 78,94  €
Last Close Price 67,08  €
Spread / Highest target 83,4%
Spread / Average Target 17,7%
Spread / Lowest Target -42,2%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG10.47%68 980
JOHNSON & JOHNSON2.01%347 446
ROCHE HOLDING LTD.16.27%245 289
MERCK AND COMPANY11.45%218 042
PFIZER-15.95%202 934
NOVARTIS15.60%199 009